Biofrontera AG (ETR:B8FK)

Germany flag Germany · Delayed Price · Currency is EUR
2.420
-0.020 (-0.82%)
Apr 29, 2026, 5:35 PM CET
2.98%
Market Cap 14.83M
Revenue (ttm) 13.19M
Net Income (ttm) -3.97M
Shares Out 6.08M
EPS (ttm) -0.65
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 78
Average Volume 565
Open 2.370
Previous Close 2.440
Day's Range 2.370 - 2.420
52-Week Range 2.160 - 2.960
Beta -0.18
RSI 38.14
Earnings Date Apr 17, 2026

About Biofrontera AG

Biofrontera AG, a biopharmaceutical company, engages in the research, development, and distribution of dermatological products in Germany, Spain, the United Kingdom, rest of Europe, the United States, and internationally. The company offers Ameluz and BF-RhodoLED lamp for the treatment of mild and moderate actinic keratoses on the face and scalp, field cancerization, and fatal squamous cell carcinoma. It also provides RhodoLED XL lamp for the treatment of multiple interspersed lesions; and Belixos, a cosmetic product for irritated and sensitive... [Read more]

Sector Healthcare
Founded 1997
Employees 76
Stock Exchange Deutsche Börse Xetra
Ticker Symbol B8FK
Full Company Profile

Financial Performance

In 2025, Biofrontera AG's revenue was 13.19 million, an increase of 8.26% compared to the previous year's 12.18 million. Losses were -3.97 million, -8.85% less than in 2024.

Financial Statements

News

There is no news available yet.